Background: Guidelines regarding the impact and value of prophylaxis or maintenance therapy in equine gastric ulcer syndrome (EGUS) are not wellestablished or defined. The merits and the magnitude of effects of prophylaxis for spontaneous or recurrent squamous gastric ulceration in horses in training are uncertain. Objectives: To pool data from randomised controlled trials (RCTs) to eliminate reporting bias and evaluate the efficacy of prophylactic omeprazole in the prevention of EGUS in training horses, and secondarily to compare prophylactic dosages of omeprazole. Study design: Meta-analysis. Methods: This meta-analysis was conducted according to the recommendations of the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. A systematic literature search identified RCTs comparing omeprazole prophylaxis with sham in prevention of EGUS. Data were analysed using the Mantel-Haenszel test method to calculate risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CIs). Primary outcome was efficacy of prophylaxis. Secondary outcome was endoscopic severity of ulceration. The influence of study characteristics on the outcomes was examined by subgroup analyses. Results: In preventing gastric ulcer occurrence, omeprazole prophylaxis was superior to sham in training horses (7 trials, 566 horses, RR 0.28, 95% CI 0.18-0.43; 23.4% in omeprazole prophylaxis vs. 77.2% in sham; high quality evidence). Prevalence of ulceration was 75.3 and 87.2% in the sham arms of the 1 mg/kg and 2 mg/kg omeprazole groups, respectively. Severity scores were significantly lower for omeprazole vs. sham (mean difference [MD] À1.05; 95% CI À1.35 to À0.69). Subgroup analyses comparing prophylactic omeprazole dosages resulted in a mean difference of À0.94 and À1.60 for the 1 and 2 mg/kg groups, respectively. Main limitations: Studies showed heterogeneity with regard to prophylactic dose. Conclusions: Omeprazole prophylaxis in active training horses significantly reduces gastric ulceration compared with no prophylaxis (sham) with the absolute effect of 566 fewer ulcers per 1000 horses treated.
Introduction
Horses in active training are prone to the development of gastric ulceration [1] [2] [3] [4] [5] with the prevalence of equine gastric ulcer syndrome (EGUS) ranging from 63 to 93% [2] [3] [4] [5] [6] [7] . Multiple factors contribute to an ulcerogenic environment for horses, potentially including housing and feeding conditions and the specific exercise and training routine used [8] . Studies, however, have failed to demonstrate associations between specific causative factors and the presence of ulceration. Consequently, prophylactic prevention of ulcers in racehorses in training is deemed logical [8] .
The treatment and prevention of EGUS is commonly approached using omeprazole, a proton pump inhibitor (PPI), which works by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system and thus inhibiting gastric acid secretion [9] . Currently, the US Food and Drug Administration (FDA) has approved the use of omeprazole at doses of 4 mg/kg daily for 28 days for the treatment of existing ulcers in horses, 2 mg/kg daily for an additional 30 days for the prevention of recurrence [9] and 1 mg/kg daily for up to 28 days for prevention of ulcers in healthy horses [10] . Data from randomised controlled trials (RCTs) indicate that efficacy can be achieved with lower doses [11, 12] , and the Australian Pesticides and Veterinary Medicines Authority (APVMA) has approved 0.5 mg/kg for ulcer prevention in horses [13] .
Randomised controlled trials evaluating the clinical effect of PPIs in EGUS treatment and prevention in race-trained horses have been variable and subject to biases. Most have evaluated only omeprazole but dose and dosing schedules have varied. Some trials have shown no difference in ulcer severity between preventive treatment and sham groups [14, 15] , while others have found significant differences [11, [16] [17] [18] [19] . More than 50% of the RCTs to date have had a reporting bias, given that horses lost to follow-up have been excluded from analysis, potentially biasing the results [11, 12, 14, 15, 18] . None of the RCTs have used sample size analysis.
To pool prophylactic treatment effects and gather real-world evidence to ultimately gain insight for clinical and research applications, we undertook a meta-analysis of data from RCTs. Our objective was to eliminate the reporting bias in the RCTs by including missing data using worst-case scenario analysis and to pool the data to evaluate the efficacy of prophylactic PPIs compared with sham in the prevention of the development of EGUS in active training horses. A secondary objective was to compare dosages of PPIs with regard to ulcer severity and the prevention of EGUS.
of gastric ulcers in active training horses using any antacid regime and a sham control. The sequence of the search strategy was as follows: 1) horses [MeSH] [3] . We then selected only randomised trials that had two groups of horses: a treatment and a sham control. The search was started from initiation of each database until 15 October 2017. Only published articles were included and no language restrictions were applied.
Inclusion criteria
For the scope of this meta-analysis, we narrowed the treatment regime to include only studies evaluating ulcer prophylaxis with PPI to prevent naturally occurring ulcers or the recurrence of squamous gastric ulceration. Studies that included glandular gastric ulceration were excluded. Modified cross-over trials with both ulcer healing and prophylactic periods were included if the prophylactic period was well defined. Intervention period 1 in these cross-over trials was the treatment of existing ulcers. At the end of intervention period 1, healing was determined with endoscopy. Intervention period 2 was the 28-day period immediately following intervention period 1. At the end of intervention period 2, horses were examined endoscopically for evidence of gastric squamous ulcer recurrence. Individual studies or studies with cross-over periods exclusively evaluating treatment of existing gastric ulcers were excluded. Only horses with endoscopic evaluation of the stomach before and after prophylactic therapy were included. There were no restrictions on the dose of PPI used, duration of prophylaxis, breed of horse, or training regime. Studies not looking at PPI were excluded. All of the studies included horses in active training; all had horses in race training and one had additional horses in western performance training [19] . Details of the acclimatisation and training details are shown in Supplementary Item 1.
Outcomes of interest
The primary outcome, assessing efficacy, was the proportion of horses with no endoscopic evidence of squamous gastric ulceration following prophylactic therapy during active training. This included both the prevention of recurrence of ulceration and the prevention of ulceration in horses with no prior history of EGUS. Secondary outcomes, assessing severity, included end-of-study gastric ulcer scores and prophylactic-related adverse drug reactions.
Data extraction
Two authors (R.J.M., L.V.M.) independently screened all studies by title or abstract for those qualifying for further retrieval (full text or abstract), and then independently reviewed these studies for eligibility, data abstraction, and quality assessment. Disagreements on study inclusion between the authors were resolved by consulting a third author (J.R.M.).
Data extracted from the studies included endoscopic findings, dosage regime, ulcer scoring system, training details and duration of follow-up. Details of the endoscopic assessment and the ulcer scoring system used were noted. The characteristics of each study including selection criteria, number of horses and treatment in each group were recorded.
Endoscopy
For each horse, the endoscopist recorded a score for the most severe gastric lesion using the 4-point equine gastric ulcer scoring system described by Andrews [16] . Ulcer grade scores 0, 1, 2 and 3 represent intact squamous mucosal epithelium, small single or small multi-focal squamous ulceration, large single or large multi-focal ulceration, and deep ulceration, respectively.
Score imputed
We derived the individual gastric ulcer scores for each horse from each study. However, one of the studies did not specify primary outcome measures [15] so we were unable to impute individual scores for this study. For this study, we calculated the standard deviation from the standard error of the mean reported in the manuscript. Horses with no evidence of ulceration were given a score of 0.
Assessment of risk of bias
The risk of bias was assessed using Cochrane criteria and the Cochrane risk of bias tool [21] . Each of the eligible studies was assessed for the risk of bias independently. The risk of bias was assessed according to the following domains: adequacy of random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other sources of biases. Each potential source of bias was graded as high, low or unclear.
Data analysis and measure of prophylactic effect
All analyses were performed using RevMan 5.3 a . In this analysis we used the worst-case scenario approach and regarded horses lost to follow-up as prophylactic treatment failures. We then assigned these horses a conservative severity score of 2. A sensitivity analysis using the data as reported in the studies (with missing data for horses lost to follow-up) showed no statistical difference in outcome when compared with this meta-analysis. Data entries in the columns of forest plots were doublechecked individually by two authors (R.J.M. and L.V.M.) to avoid data entry errors.
The combined risk ratio (RR) with 95% confidence intervals (95% CI) were calculated in each treatment group for the primary outcome of ulcer prevalence (dichotomous variable). The mean differences (MD) between treatment groups were calculated with 95% CI for the secondary outcome of ulcer score (continuous variable). The number needed to treat (NNT) to prevent squamous gastric ulceration or recurrence of ulceration with PPI was calculated. Pooled analyses were performed with the Mantel-Haenzel method using both fixed-effect and random-effect models with interpretation based on the level of heterogeneity of the studies. Findings of heterogeneity were investigated according to the following predefined criteria: multicentre vs. single centre, country of origin, horse breed, housing status, feeding regime, blinding, omeprazole dosage, duration of prophylaxis and ulcer scoring system. The I 2 statistic, the P-value from the v 2 test and inspection of the forest plots was used to determine heterogeneity [22] . An I 2 <25% was considered to indicate low heterogeneity and an I 2 >75% indicated high heterogeneity [23] . Where significant heterogeneity was detected, we investigated possible explanations and summarised the data using a random-effects model. Sub-group analysis was also performed if the reason for heterogeneity was identified. The summary of findings table was developed following the GRADE approach [24] .
Results
The literature and hand searches identified 379 unique citations, which were reviewed by two authors (L.V.M. and R.J.M.); 27 studies were identified for full text review, following which 20 were excluded due to methodological incompatibilities with the meta-analytical approach, in most cases due to lack of a suitable control arm. The remaining seven studies were included for quantitative synthesis (Fig 1) .
Study characteristics
The seven studies analysed included a total of 654 horses ( Table 1 ). All of the studies had a sham arm, and three studies had more than two arms (Table 1) . Six of the studies were multicentre studies (Table 1) . Three studies included only Thoroughbred horses, with the remaining four studies including horses of multiple or different breeds (Table 1) . Age range of the included horses was 1-11 years with body weight ranging from 308 to 563 kg (Table 1) . Overall, 288 mares, 216 geldings, 98 stallions, 31 geldings or stallions and 21 horses of unknown sex were included in the studies (Table 1 ). All seven studies included analyses of the prevention of squamous gastric ulceration with PPI in active training horses ( Table 1 ). The PPI used in all seven studies was omeprazole (Table 1) . Three studies included horses that had no previous history of squamous gastric ulceration, and four were modified cross-over studies which focused on the prevention of recurrence of ulceration following prior treatment for squamous gastric ulceration and therefore included horses with a previous history of ulceration (Table 1) . Training methods were variable, but all 7 studies included horses in training, thus horses were all in an ulcerogenic environment (Supplementary Item 1).
Quality appraisal
The quality of the seven included studies was good, with only three studies having some methodological flaws [14, 15, 19] . Overall, the risk of bias was low (Figs 2 and 3 ). There was no risk of bias with regard to sequence generation, allocation concealment, blinding, incomplete attrition or selective reporting biases. All studies included horses in race training, and one of the studies [19] included additional horses in other exercise regimes. In all studies, the chance of selection or allocation bias was minimal because the intervention in all trials was prophylaxis. The performance bias was not relevant because horses are blinded to their treatment. Attrition rates were low or well described in each of the studies. Other possible biases were the inclusion of different breeds of horses and the lack of standardisation in training regimes. In more than 50% of the studies, the horses that were lost to follow-up were excluded from analysis. However, we overcame this reporting bias by including these horses in our meta-analysis as prophylactic failures under an intention-totreat (ITT) analysis.
Sample sizes ranged from 20 to 175, and none of the studies utilised sample size calculations in support of the enrollment numbers.
No protocol violations were apparent in any of the studies. Missing data were handled by performing worst-case scenario analysis.
Primary outcome
Six of the seven RCTs defined the effectiveness of gastric ulcer prevention by the absence (vs. presence) of endoscopic evidence of ulceration. This dichotomous gastric ulcer prevalence was evaluated in 566 horses in training given any dose of prophylactic omeprazole for between 7 and 28 days. Overall, with an ITT analysis, 23% of the horses had squamous gastric ulceration in the omeprazole prophylactic group compared with 77% in the no prophylaxis group at study end (Fig 4a) . There was a statistically significant benefit of omeprazole prophylaxis compared with no The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
prophylaxis in the prevention of gastric ulcer or recurrence in horses in training (RR = 0.28; 95% CI 0.18-0.43; NNT 1.86). Heterogeneity between trial results was statistically significant (test of heterogeneity v 2 = 18.10; df = 5, P = 0.003; I 2 = 72%; random effects model). Exploration of the possible sources of the heterogeneity showed that the prophylactic dose of omeprazole used and the horses' prior history of ulceration were significant factors contributing to the heterogeneity.
Subgroup analysis of the primary outcome
For the subgroup analysis on the dose of omeprazole used to prevent squamous gastric ulceration in horses in training, two doses were identified: 1 and 2 mg/kg. Low numbers of horses in the 0.5 and the 4 mg/ kg dosage groups precluded their inclusion in the subgroup analysis. The test of heterogeneity for 1 mg/kg gave a v 2 = 3.9, df = 3, P = 0.27, I 2 = 23%, while that for 2 mg/kg gave v 2 = 0.172, df = 2, P = 0.42, I 2 = 0%. Omeprazole at 1 mg/kg significantly prevented ulceration in horses compared with sham (RR 0.26; 95% CI 0.20-0.35; NNT 1.80; Fig 4b) . Similarly, omeprazole at 2 mg/kg significantly prevented gastric ulcers in horses compared with sham (RR 0.22; 95% CI 0.12-0.38; NNT 1.50; Fig 4c) .
For the subgroup analysis based on the horses' prior history of ulceration, two indications were identified: 1) prophylactic omeprazole to prevent development of ulcers in healthy horses with no previous history of squamous gastric ulceration, and 2) prophylactic omeprazole to prevent the recurrence of squamous gastric ulceration in horses with a previous history of ulceration. The test of heterogeneity for horses with no previous history of ulceration gave a v 2 = 9.03, df = 2, P = 0.01, I 2 = 78%, random effects model (Fig 5a) , while that for horses with a previous history of ulceration was v 2 = 0.50, df = 2, P = 0.78, I 2 = 0% (Fig 5b) . Omeprazole significantly prevented ulceration in horses with no previous ulcer history compared with sham (RR 0.31; 95% CI 0.14-0.71; NNT 2.3; Fig 5a) . Similarly, omeprazole in horses with a previous history of ulceration significantly prevented recurrence compared with sham (RR 0.23; 95% CI 0.17-0.31; NNT 1.5; Fig 5b) .
Secondary outcome
All seven RCTs reported on the severity of squamous gastric ulceration using a continuous gastric ulcer score determined at endoscopy between 7 and 28 days after prophylactic omeprazole (any dose) was given to horses in active training (n = 593). The end-of-study ulcer score was statistically significantly lower in horses given prophylaxis compared with those in the sham group (MD À1.05; 95% CI À1.40 to À0.69; Fig 6a) . There was statistically significant heterogeneity between trial results (heterogeneity test; v 2 = 38.36, df = 6, P<0.00001; I 2 = 84%; random effects model).
Subgroup analysis of the secondary outcome
For the subgroup analysis based on omeprazole dosage used in gastric ulcer prophylaxis, two doses were identified: 1 and 2 mg/kg. The test of heterogeneity for 1 mg/kg gave v 2 = 20.58, df = 3, P<0.0001, I 2 = 85% random effects model (Fig 6b) , while that for 2 mg/kg gave v 2 = 2.29, df = 2, P = 0.3, I 2 = 13%, fixed effects model (Fig 6c) . Overall, the mean gastric score for the 1 mg/kg group was 0.30 AE 0.65 compared with control group of 1.31 AE 1.02 (P<0.001). The pooled mean difference was À0.94 (95% CI À1.35 to À0.52; random effects model). Overall, the mean gastric score for the 2 mg/kg group was 0.22 AE 0.46 compared with the mean gastric score for the sham group of 1.87 AE 1.05 (P<0.001). The pooled mean difference was À1.6 (95% CI À1.89 to À1.30; fixed effects model).
Adverse events with omeprazole
Six of the seven studies reported no treatment-related adverse events in the randomised groups [11, [15] [16] [17] [18] [19] . One study [14] did not specify the relatedness of the adverse events to the medication, namely lameness in three horses. In no study was the adverse event rate different between White (2007) [19] Allocation concealment (selection bias) Random sequence generation (selection bias)
Blinding of participants and personnel (performance bias) Blinding of outcome assessment (detection bias) Incomplete outcome data (attrition bias) Selective reporting (reporting bias) Other bias 
Discussion
The results of this meta-analysis determined that omeprazole prevented squamous gastric ulceration in horses in training. Seventy-seven percent of horses given no prophylaxis developed ulcers, while only 23% treated prophylactically had ulceration. There was a significant relative risk reduction of 70% in the prevention of squamous gastric ulceration in horses with no previous history of ulceration, and a slightly greater significant risk ratio reduction of 87% in the prevention of recurrence of squamous gastric ulceration in horses with a prior history of ulceration. The greater reduction in risk in horses with a previous history of squamous gastric ulceration might reflect the longer treatment time (56 vs. 28 days) due to the initial treatment period to treat existing ulcers before the prophylactic period. Alternatively, those horses might be more prone to squamous gastric ulceration and thus benefit from any reduction in gastric acid secretion. Genetic factors might underlie baseline levels of gastric acid secretion. Variability in stress tolerance might manifest in different levels of gastric acid secretion, resulting in underlying resilience shown in horses with no prior history of ulceration. Omeprazole essentially brings the presence of ulcers to zero, regardless of prior history of ulcers in animals, thus resulting in a greater benefit for horses with a previous history of squamous gastric ulceration. Prophylactic omeprazole dosages ranged from 0.5 to 4 mg/kg. The risk ratio for ulcer prevention were similar with 1 and 2 mg/kg dosages (0.26 and 0.22, respectively), indicating that the low dose of 1 mg/kg would be just as effective as the FDA-approved dose of 2 mg/kg. The NNT for each dose was similar at 1.8 and 1.5 for the 1 and 2 mg/kg groups, respectively. While the 0.3-horse advantage for the higher dosage is not clinically relevant, the mean difference between prophylaxis and sham groups in the severity score was 0.66 greater for the 2 mg/kg dosage compared with the 1 mg/kg dose.
In a study not included in this meta-analysis, the ultra-low dose of 0.5 mg/kg of omeprazole was shown to be equivalent to 1 mg/kg for the prevention of EGUS [12] . In Australia 0.5 mg/kg is the registered prophylactic dose [13] . However, post hoc analysis of data from McClure et al. [18] showed no differences in prevention between sham and 0.5 mg/ kg (P = 0.54) RR À1.13 (0.77, 1.64). The implications for clinical practice as to which prophylactic omeprazole dose is optimal, 0. [19] Endo (2012) [14] Total (95% CI) Total events Heterogeneity: τ 2 = 0.19; χ 2 = 18.10, df = 5 (P = 0.003); l 2 = 72% Test for overall effect: Z = 5.83 (P < 0.00001) Total (95% CI) Total events Heterogeneity: χ 2 = 3.90, df = 3 (P = 0.27); l 2 = 23% Test for overall effect: Z = 9.05 (P < 0.00001) Total (95% CI) Total events Heterogeneity: χ 2 = 1.72, df = 2 (P = 0.42); l 2 = 0% Test for overall effect: Z = 5.25 (P < 0.00001) [19] White (2007) [19] Endo (2012) [14] Andrews (1999) [16] Total (95% CI) Heterogeneity: τ 2 = 0.19; χ 2 = 38.36, df = 6 (P < 0.00001); I 2 = 84% Test for overall effect: Z = 5.72 (P < 0.00001) Total (95% CI) Heterogeneity: τ 2 = 0.15; χ 2 = 20.58, df = 3 (P = 0.0001); I 2 = 85% Test for overall effect: Z = 4.42 (P < 0.00001) Total (95% CI) Heterogeneity: χ 2 = 2.29, df = 2 (P = 0.32); I 2 = 13% Test for overall effect: Z = 10.64 (P < 0.00001) No studies have evaluated the economic implications of prophylaxis, but it would seem that prophylaxis would be financially advantageous to ulcer treatment, given the high prevalence of ulceration that occurs without prophylaxis.
There have been no previous reviews or meta-analyses of RCTs evaluating the use of PPIs for ulcer prevention in horses. The results of this meta-analysis confirm the high prevalence of gastric ulcers in horses in training reported in the literature. Limitations of this analysis include the small number of trials meeting inclusion criteria. However, the majority of trials analysed were of high quality and the evidence was overwhelmingly in favour of prophylaxis.
A recent consensus statement of the European College of Equine Internal Medicine [8] recommends the use of omeprazole for the prevention of ulcers in horses; however, there are no specific guidelines for their use with regards to dosage and duration of therapy [8] . This review has identified some directions for further research. Future trials should compare the lower dosage of 0.5 mg/kg of omeprazole, other PPIs, or alternative therapies such as H2 receptor antagonists or other antacids, such as sucralfate, with sham. Trials looking at alternate day dosing schedules and duration of prophylaxis are also warranted. No studies have evaluated prophylaxis for longer than 28 days, but it appears from the high prevalence, high efficacy and low incidence of any adverse event associated with the medication that prophylaxis should be continued for as long as a horse is in an ulcerogenic training environment. While no apparent adverse drug reactions were noted, the long-term implications of PPIs used prophylactically or even therapeutically is unknown and has not yet been evaluated.
The importance of prophylaxis is evident by the overall NNT of 1.8, meaning 1.8 horses must be treated with prophylactic omeprazole to prevent one additional squamous gastric ulcer from developing in horses in training. This low number shows that virtually all horses given prophylaxis will benefit. For horses with a prior history of squamous gastric ulceration the NNT was even lower at 1.5. The NNT for horses without a prior history was 2.3. The clinical implications are that with omeprazole prophylaxis there are 556 per 1000 fewer horses with squamous gastric ulceration.
